p53 protein expression in human multidrug-resistant CEM lymphoblasts

被引:9
作者
Rafki, N
LiautaudRoger, F
Devy, L
Trentesaux, C
Dufer, J
机构
[1] UNIV REIMS,UFR PHARM,GIBSA,LAB PHYSIOL CELLULAIRE,F-51100 REIMS,FRANCE
[2] INST JEAN GODINOI,F-51056 REIMS,FRANCE
[3] UNIV REIMS,UFR PHARM,GIBSA,MOL BIOL LAB,F-51100 REIMS,FRANCE
关键词
p53 protein expression; multidrug resistance; leukemic cell line;
D O I
10.1016/S0145-2126(96)00086-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A role for p53 in the regulation of multidrug-resistance (MDR) has been postulated as wild-type p53 suppresses and mutant p53 specifically activates the mdr? promoter. Moreover, changes in p53 expression and/or functions could be implicated in drug resistance. As the parental lymphoblastic CCRF-CEM cell line has been described as expressing a mutated form of p53, we have examined p53 and mdm2 protein levels in the human multidrug-resistant CEM-VLB cell line variant. These drug-resistant CEM-VLB cells, which have increased expressions of mdr1 and P-glycoprotein, displayed p53 and mdm2 protein expressions similar to those observed in their sensitive CCRF-CEM counterparts. Treatment of these drug-resistant cells with non-toxic doses of the resistance-inducing drug vinblastin induced a strong increase in p53 protein and mRNA but was ineffective on mdm2 protein expression, or mdr1 mRNA expression. These data indicate that mutant p53 protein was not overexpressed in these MDR cells. This overexpression could be induced by microtubule-active drug treatment, but, as previously observed in other sensitive cell lines, mutant p53 from these MDR cells was unable to positively regulate mdm2 gene product expression. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:147 / 152
页数:6
相关论文
共 38 条
  • [1] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY
    BARAK, Y
    JUVEN, T
    HAFFNER, R
    OREN, M
    [J]. EMBO JOURNAL, 1993, 12 (02) : 461 - 468
  • [2] INCREASED ACCUMULATION OF P53 PROTEIN IN CISPLATIN-RESISTANT OVARIAN CELL-LINES
    BROWN, R
    CLUGSTON, C
    BURNS, P
    EDLIN, A
    VASEY, P
    VOJTESEK, B
    KAYE, SB
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) : 678 - 684
  • [3] Brugal G, 1984, Methods Achiev Exp Pathol, V11, P1
  • [4] INTERACTIONS BETWEEN P53 AND MDM2 IN A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY
    CHEN, CY
    OLINER, JD
    ZHAN, QM
    FORNACE, AJ
    VOGELSTEIN, B
    KASTAN, MB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) : 2684 - 2688
  • [5] REGULATION OF TRANSCRIPTION FUNCTIONS OF THE P53 TUMOR-SUPPRESSOR BY THE MDM-2 ONCOGENE
    CHEN, JD
    LIN, JY
    LEVINE, AJ
    [J]. MOLECULAR MEDICINE, 1995, 1 (02) : 142 - 152
  • [6] FREQUENT MUTATIONS IN THE P53 TUMOR SUPPRESSOR GENE IN HUMAN LEUKEMIA T-CELL LINES
    CHENG, J
    HAAS, M
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (10) : 5502 - 5509
  • [7] MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53
    CHIN, KV
    UEDA, K
    PASTAN, I
    GOTTESMAN, MM
    [J]. SCIENCE, 1992, 255 (5043) : 459 - 462
  • [8] SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION
    CHOMCZYNSKI, P
    SACCHI, N
    [J]. ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) : 156 - 159
  • [9] IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES)
    CORDELL, JL
    FALINI, B
    ERBER, WN
    GHOSH, AK
    ABDULAZIZ, Z
    MACDONALD, S
    PULFORD, KAF
    STEIN, H
    MASON, DY
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) : 219 - 229
  • [10] P-GLYCOPROTEIN IS NOT EXPRESSED IN A MAJORITY OF COLORECTAL CARCINOMAS AND IS NOT REGULATED BY MUTANT P53 IN-VIVO
    DEANGELIS, P
    STOKKE, T
    SMEDSHAMMER, L
    LOTHE, RA
    LEHNE, G
    CHEN, Y
    CLAUSEN, OPF
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 307 - 311